Are Wall Street Analysts Predicting West Pharmaceutical Stock Will Climb or Sink?
Wall Street analysts covering West Pharmaceutical (WST) have a consensus 'Strong Buy' rating, with 14 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' The bullish sentiment has slightly decreased from last month. The mean price target of $401.31 suggests a 14.7% upside, while the highest target at $459 implies a 31.2% potential gain.
How this was made
The 30-second read
Why it matters
The new mean and high price targets imply a 14‑31% upside, which could attract buying interest.
Market read
Analyst target revisions may influence short‑term price action and sector sentiment.
What to watch
Potential supply chain or regulatory risks not addressed in the consensus.
Background
West Pharmaceutical Services (WST) is a US‑listed medical device maker. Analyst coverage recently updated price targets.
Ticker impact
Analyst consensus of Strong Buy with new mean price target $401.31 and high target $459, indicating upside.
Modest upside of 10‑15% if targets are incorporated.
New price targets suggest upside but rating unchanged; market may price in gradually.
Market effects
May lift peer pharma stocks as analysts show confidence in the sector.
US pharma sector could see slight bullish pressure.
Limited to US-listed pharma investors.
Counterpoint
Rating unchanged suggests limited conviction; price targets may be optimistic.
Key entities
- companyWest Pharmaceutical Services
US‑listed medical device manufacturer (ticker WST).
- analyst_firmBNP Paribas
Initiated coverage with Outperform rating and $447 target.
